Abstract

Elevated plasma low-density lipoprotein (LDL) cholesterol is considered as a risk factor for atherosclerosis. Because the hepatic LDL receptor (LDLR) uptakes plasma lipoproteins and lowers plasma LDL cholesterol, the activation of LDLR is a promising drug target for atherosclerosis. In the present study, we identified the naturally occurring alkaloid piperine, as an inducer of LDLR gene expression by screening the effectors of human LDLR promoter. The treatment of HepG2 cells with piperine increased LDLR expression at mRNA and protein levels and stimulated LDL uptake. Subsequent luciferase reporter gene assays revealed that the mutation of sterol regulatory element-binding protein (SREBP)-binding element abolished the piperine-mediated induction of LDLR promoter activity. Further, piperine treatments increased mRNA levels of several SREBP targets and mature forms of SREBPs. However, the piperine-mediated induction of the mature forms of SREBPs was not observed in SRD–15 cells, which lack insulin-induced gene–1 (Insig–1) and Insig–2. Finally, the knockdown of SREBPs completely abolished the piperine-meditated induction of LDLR gene expression in HepG2 cells, indicating that piperine stimulates the proteolytic activation of SREBP and subsequent induction of LDLR expression and activity.

Highlights

  • High-plasma low-density lipoprotein (LDL) cholesterol levels are a major risk factor for atherosclerosis and coronary heart disease [1]

  • Piperine treatments led to increased endogenous LDL receptor (LDLR) mRNA levels in HepG2 cells after 24 h (Fig 1B), and the effect was dose dependent (Fig 2A)

  • The present data demonstrate that the alkaloid piperine stimulates LDLR gene expression and uptake of LDL particles in cultured hepatocytes

Read more

Summary

Introduction

High-plasma low-density lipoprotein (LDL) cholesterol levels are a major risk factor for atherosclerosis and coronary heart disease [1]. The liver is a major organ that uptakes LDL particles via LDL receptor (LDLR)-meditated endocytosis and has the ability to metabolize up to 70% of plasma LDL [2]. Increased LDLR expression in the liver ameliorates atherogenic lipid profiles and suppresses plasma LDL-cholesterol levels. LDLR expression is regulated by transcription, mRNA degradation, post-translational modification, and protein degradation [3,4,5,6]. PLOS ONE | DOI:10.1371/journal.pone.0139799 October 2, 2015

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call